The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GH | +232.8% | -15.75% | -3.37% | +203% |
| S&P | +14.08% | +93.57% | +14.12% | +136% |
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.
Learn about some of the leading cancer stocks in the U.S. stock market this year.
A pair of crushing beats propelled the company's stock well higher.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $265.20M | 38.5% |
| Gross Profit | $171.61M | 46.7% |
| Gross Margin | 64.71% | 3.6% |
| Market Cap | $7.79B | 176.1% |
| Market Cap / Employee | $3.86M | 0.0% |
| Employees | 2K | 13.6% |
| Net Income | -$92.73M | 13.9% |
| EBITDA | -$89.59M | 16.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $580.01M | -15.7% |
| Accounts Receivable | $115.59M | 30.7% |
| Inventory | 90.5 | 25.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.30B | -0.9% |
| Short Term Debt | $26.40M | -3.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.33% | 2.4% |
| Return On Invested Capital | -29.65% | -5.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$45.76M | 17.2% |
| Operating Free Cash Flow | -$35.41M | 30.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -62.61 | -37.83 | -25.66 | -25.46 | -45.84% |
| Price to Sales | 5.12 | 6.82 | 7.79 | 8.64 | 111.88% |
| Price to Tangible Book Value | -53.27 | -35.29 | -24.71 | -24.72 | -38.20% |
| Enterprise Value to EBITDA | -37.02 | -58.38 | -74.30 | -95.37 | 221.80% |
| Return on Equity | -3883.9% | -337.2% | -609.3% | -4584.5% | 946.38% |
| Total Debt | $1.34B | $1.31B | $1.33B | $1.33B | -0.97% |
GH earnings call for the period ending October 30, 2021.
GH earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
